Recombinetics, Inc.

Recombinetics, Inc. is a biotechnology firm specializing in advanced gene editing solutions for animals, particularly focusing on custom gene-edited swine models that enhance preclinical research effectiveness. Founded in 2008 and headquartered in St. Paul, US, Recombinetics, Inc.

specializes in creating gene-edited swine models for biomedical and agricultural research. The company was co-founded by Perry Hackett and Scott Fahrenkrug. Recombinetics has raised a total of USD 34 mn through its Series A funding round in August 2018, representing its only known financing round to date. With a current valuation of USD 260 mn, the firm has completed eight investment deals over its history.

Recombinetics specializes in advanced animal gene editing solutions, primarily focusing on custom gene-edited swine models designed for translational preclinical research. These models aim to streamline the regulatory preclinical pathway, presenting a viable alternative to traditional nonhuman primate usage in biomedical research and agricultural applications. The core product offerings are designed for pharmaceutical and biotechnology companies, academic institutions, and research organizations seeking reliable preclinical data to support their development programs. The company serves a global client base, including research entities in North America, Europe, and Asia, providing innovative solutions that enhance the health, welfare, and sustainability of food animals.

Recombinetics generates revenue through strategic partnerships and direct business-to-business transactions, where clients engage the company for its specialized gene-editing services and swine models. The pricing structure is typically based on project terms or contractual agreements tailored to the specific needs of clients, which may involve long-term collaborations focused on research and development initiatives. Transactions include the provision of customized gene editing services essential for clients' preclinical trials. Key products include proprietary gene-edited swine models that facilitate translational research, thus attracting pharmaceutical companies and research institutions aiming to advance their therapeutic solutions.

Recombinetics is focused on expanding its product offerings and geographic reach. The company plans to introduce new gene editing technologies aimed at enhancing agricultural practices and biomedical research, with initial launches expected by 2024. Following its recent funding round in August 2018, which raised USD 34 mn, Recombinetics aims to utilize these resources to support the development of its new products and expand into markets in Asia and Europe by 2025. This strategic growth plan is designed to strengthen its position within the biotechnology sector.